We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fast, Accurate and Portable Molecular Analyzer to Revolutionize Diagnostics

By LabMedica International staff writers
Posted on 03 Sep 2022
Print article
Image: Genomadix Cube is a fast, accurate, and portable molecular analyzer that uses the same PCR technology as a full service lab (Photo courtesy of Genomadix)
Image: Genomadix Cube is a fast, accurate, and portable molecular analyzer that uses the same PCR technology as a full service lab (Photo courtesy of Genomadix)

The increase in the prevalence of infectious diseases and the onset of the COVID-19 pandemic has led to an increase in lab testing in order to keep pace with rising cases across the world. However, traditional lab-based tests can take days to weeks for results. Now, a fast, accurate, and portable DNA analyzer goes from sample to result in approximately an hour and delivers quality results outside of a lab.

Genomadix Inc.’s (Kanata, ON, Canada) Genomadix Cube is a portable, molecular analyzer that uses polymerase chain reaction (PCR) technology to generate relatively quick, accurate test results, outside of a healthcare facility. Designed to be used as a decentralized testing option, the analyzer is especially helpful for remote communities and remote industries where access to a full lab may be difficult. Samples are collected and inserted into a single-use DNA test cartridge. Inside the analyzer, the cartridge extracts the DNA/RNA and makes millions of copies based on PCR. An optical system detects the increased fluorescence and algorithms automatically generate a test result.

The Genomadix Cube automates complex and tedious manual procedures, advancing sample to result DNA/RNA testing in clinical, environmental, infectious disease, and precision medicine. The testing system already delivers environmental testing for potentially deadly Legionella bacteria in water sources such as building cooling towers and CYP2C19 genotype guided antiplatelet therapy in Europe with efforts underway for US authorization. Additionally, a COVID-19 product has been developed with introduction slated (pending authorization) for later in 2022. These tests are run using their own unique software on the Genomadix Cube.

Related Links:
Genomadix Inc. 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.